Table 1 Correlations between ATR expression and clinicopathological characteristics in breast cancer patients
From: Clinical and functional significance of tumor/stromal ATR expression in breast cancer patients
Parameter | Total (n = 103) (%) | ATR in stromal fibroblasts | Pvalue | ||
High | Intermediate | Low | |||
Stage | |||||
T2 | 30 (29.13) | 6 (5.83) | 17 (16.50) | 7 (6.80) | |
T3 | 29 (28.16) | 10 (9.71) | 13 (12.62) | 6 (5.83) | 0.3308 |
T4 | 43 (41.75) | 14 (13.59) | 14 (13.59) | 15 (14.56) | |
Tx | 1 (0.97) | 0 (0.00) | 1 (0.97) | 0 (0.00) | |
KI-67 index | |||||
0 | 85 (84.16) | 26 (24.75) | 37 (36.63) | 23 (22.77) | |
≤ 15 | 2 (1.98) | 0 (0.00) | 2 (1.98) | 0 (0.00) | 0.7652 |
>15 | 14 (13.86) | 5 (4.95) | 5 (4.95) | 4 (3.96) | |
HIS subtype | |||||
None invasive | 1 (0.97) | 1 (0.97) | 0 (0.00) | 0 (0.00) | |
Invasive ductal Ca | 85 (82.52) | 23 (22.33) | 40 (38.83) | 22 (21.36) | |
1,4 | 3 (2.91) | 1 (0.97) | 1 (0.97) | 1 (0.97) | 0.5887 |
Invasive ductal Ca with DCIS | 11 (10.68) | 3 (2.91) | 4 (3.88) | 4 (3.88) | |
Infiltrating lobular Ca | 1 (0.97) | 0 (0.00) | 0 (0.00) | 1 (0.97) | |
3, 4 | 1 (0.97) | 1 (0.97) | 0 (0.00) | 0 (0.00) | |
Other | 1 (0.97) | 1 (0.97) | 0 (0.00) | 0 (0.00) | |
Recurrence | |||||
No | 63 (61.76) | 18 (17.65) | 35 (34.31) | 10 (9.80) | 0.0017 |
Yes | 39 (38.24) | 11 (10.78) | 10 (9.80) | 18 (17.65) | |
Grade | |||||
G1 | 3 (2.91) | 1 (0.97) | 1 (0.97) | 1 (0.97) | |
G2 | 46 (44.66) | 9 (8.74) | 27 (26.21) | 10 (9.71) | 0.0473 |
G3 | 54 (52.43) | 20 (19.42) | 17 (16.50) | 17 (16.50) | |
Progression | |||||
No | 73 (72.28) | 13 (12.87) | 40 (39.60) | 20 (19.81) | 0.0003 |
Yes | 28 (27.72) | 14 (13.86) | 4 (3.96) | 18 (9.9) | |
Survival status | |||||
Alive | 84 (81.55) | 24 (23.30) | 45 (43.69) | 15 (14.56) | < 0.0001 |
Dead | 19 (18.45) | 6 (5.83) | 0 (0.00) | 13 (12.62) | |
Duration of clinical follow-up (years, mean ± SD) | 4.16500000 | 5.00755556 | 3.87464286 | 0.0390 | |
Parameter | Total (n = 103) (%) | ATR in cancer cells | Pvalue | ||
High | Intermediate | Low | |||
Tumor size | |||||
≤ 5 | 35 (40.23) | 7 (8.05) | 15 (17.24) | 13 (14.94) | 0.4008 |
>5 | 52 (59.77) | 8 (9.20) | 17 (19.54) | 27 (31.03) | |
Stage | |||||
T2 | 30 (29.13) | 6 (5.83) | 12 (11.65) | 12 (11.65) | |
T3 | 29 (28.16) | 6 (5.83) | 10 (9.71) | 13 (12.62) | 0.6772 |
T4 | 43 (41.75) | 6 (5.83) | 16 (15.53) | 21 (20.39) | |
Tx | 1 (0.97) | 1 (0.97) | 0 (0.00) | 0 (0.00) | |
KI-67 index | |||||
0 | 85 (84.16) | 13 (12.87) | 32 (31.68) | 40 (39.60) | 0.1525 |
≤ 15 | 2 (1.98) | 0 (0.00) | 1 (0.99) | 1 (0.99) | |
>15 | 14 (13.86) | 6 (5.94) | 3 (2.97) | 5 (4.95) | |
HIS subtype | |||||
None invasive | 1 (0.97) | 0 (0.00) | 1 (0.97) | 0 (0.00) | |
Invasive ductal Ca | 85 (82.52) | 13 (12.62) | 33 (32.04) | 39 (37.86) | |
1,4 | 3 (2.91) | 0 (0.00) | 1 (0.97) | 2 (1.94) | 0.1336 |
Invasive ductal Ca with DCIS | 11 (10.68) | 4 3.88) | 2 (1.94) | 5 (4.85) | |
Infiltrating lobular Ca | 1 (0.97) | 0 (0.00) | 1 (0.97) | 0 (0.00) | |
3, 4 | 1 (0.97) | 1 (0.97) | 0 (0.00) | 0 (0.00) | |
Other | 1 (0.97) | 1 (0.97) | 0 (0.00) | 0 (0.00) | |
Recurrence | |||||
No | 63 (61.76) | 14 (13.73) | 26 (25.49) | 23 (22.55) | 0.1000 |
Yes | 39 (38.24) | 5 (4.90) | 11 (10.78) | 23 (22.55) | |
Grade | |||||
G1 | 3 (2.91) | 1 (0.97) | 1 (0.97 | 1 (0.97) | |
G2 | 46 (44.66) | 10 (9.71) | 14 (13.59) | 22 (21.36) | 0.6015 |
G3 | 54 (52.43) | 8 (7.77) | 23 (22.33) | 23 (22.33) | |
Progression | |||||
No | 73 (72.28) | 17 (16.83) | 29 (28.71) | 27 (26.73) | 0.0570 |
Yes | 28 (27.72) | 2 (1.98) | 9 (8.91) | 17 (16.83) | |
Survival status | |||||
Alive | 84 (81.55) | 18 (17.48) | 36 (34.95) | 30 (29.13) | 0.0006 |
Dead | 19 (18.45) | 1 (0.97) | 2 (1.94) | 16 (15.53) | |
Duration of clinical follow-up (years) | 4.16500000 | 5.00755556 | 3.87464286 | 0.1883 | |